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Background. Data on the association between acute
infections and venous thromboembolism (VTE) are
sparse. We examined whether various hospital-diag-
nosed infections or infections treated in the commu-
nity increase the riskofVTE.
Methods. We conducted this population-based case–
control study in Northern Denmark (population
1.8 million) using medical databases. We identified
all patients with a first hospital-diagnosed VTE
during the period 1999–2009 (n = 15 009). For
each case, we selected 10 controls from the general
population matched for age, gender and county of
residence (n = 150 074). We identified all hospital-
diagnosed infections and community prescriptions
for antibiotics 1 year predating VTE. We used odds
ratios from a conditional logistic regression model to
estimate incidence rate ratios (IRRs) of VTE within
different time intervals of thefirst year after infection,
controlling forconfounding.
Results. Respiratory tract, urinary tract, skin, intra-
abdominal and bacteraemic infections diagnosed in
hospital or treated in the community were associ-
ated with a greater than equal to twofold increased
VTE risk. The association was strongest within the
first 2 weeks after infection onset, gradually declin-
ing thereafter. Compared with individuals without
infection during the year before VTE, the IRR for
VTE within the first 3 months after infection was
12.5 (95% confidence interval (CI): 11.3–13.9) for
patients with hospital-diagnosed infection and 4.0
(95% CI: 3.8–4.1) for patients treated with antibiot-
ics in the community. Adjustment for VTE risk fac-
tors reduced these IRRs to 3.3 (95% CI: 2.9–3.8)
and 2.6 (95% CI: 2.5–2.8), respectively. Similar
associations were found for unprovoked VTE and
for deep venous thrombosis and pulmonary embo-
lism individually.
Conclusions. Infectionsarea risk factor forVTE.
Keywords: antibacterial agents, deep venous thrombo-
sis, infections, pulmonary embolism, venous throm-
boembolism.
Introduction
Any association between acute infection and ve-
nous thromboembolism (VTE) is of major clinical
importance owing to the high rates of both condi-
tions [1]. VTE affects more than 1 in a 1000 individ-
uals each year in Western populations [2–4]. It
occurs predominantly in the deep vessels of the
lower limbs (i.e. deep venous thrombosis; DVT) [2–
4], with a risk of serious complications such as
pulmonary embolism (PE) and post-thrombotic syn-
drome [2, 4]. Acute infection and the associated
systemic inflammation may increase the risk of
VTE [1, 5] owing to one or more of the three precipit-
ants of venous thrombosis proposed by Virchow:
venous stasis, increased coagulability and vessel
wall damage [6, 7].
Available evidence for an association between acute
infection and VTE is limited [1, 8–10], and no stud-
ies have been conducted to examine the magnitude
and duration of increased VTE risk associated with
various infections either diagnosed in hospital or
treated in the community. Therefore, we examined
whether patients with hospital-diagnosed or com-
munity-treated infections were at increased risk of
subsequent VTE.
Materials and methods
Setting
This study was conducted in northern Denmark, an
area with 1.8 million inhabitants (approximately
30% of the Danish population). Since the beginning
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of 1998, complete computerized prescription records
have been available for this population. Our study
period began on 1 January 1999, thus providing at
least1 yearofprescriptionhistory forallstudypartic-
ipantsandendedon31December2009.
The Danish National Health Service provides univer-
sal tax-supported healthcare, guaranteeing unre-
stricted access toprimary and secondary care, free at
the point of delivery and providing partial reimburse-
ment for prescribed medications, including antibiot-
ics [11].Accurateandunambiguous linkageofall reg-
istries at the individual level is possible in Denmark
using the unique central personal registry number
assigned to each Danish resident at birth or upon
immigration [12].
Venous thromboembolism
We used the Danish National Registry of Patients
(DNRP) [13], covering all Danish hospitals, to iden-
tify all patients in the region with a first VTE, de-
fined by an incident inpatient or outpatient (clinic or
emergency room visit) diagnosis of lower limb DVT
or PE, during the study period. The DNRP contains
data on dates of inpatient admission and discharge
from nonpsychiatric hospitals since 1977 and of
emergency room and hospital outpatient clinic visits
since 1995 [13]. Each discharge is associated with
one primary diagnosis and one or more secondary
diagnoses classified according to the International
Classification of Diseases, 8th revision (ICD-8) until
the end of 1993 and the 10th revision (ICD-10)
thereafter [13].
We identified both primary and secondary diagnoses
ofDVT andPE in theDNRP. Patients coded as having
bothDVTandPEwereclassifiedasPEpatients.Tore-
duce the impact of potential coding errors, we ex-
cludedpatientswithan incidentoutpatientdiagnosis
of PE, but without a subsequent inpatient diagnosis
of any VTE. In a secondary analysis, we focused on
cases with unprovoked VTE by excluding patients
with the following classical risk factors: pregnancy,
major trauma, fracture or surgery within 3 months
precedingVTE,andpre-existing cancer oranewcan-
cer diagnosis within 3 months after VTE [14].
The date of the first hospital diagnosis of a VTE was
considered the indexdate.
Population controls
We used the Danish Civil Registration System
to select 10 population controls for each case,
matched for age (birth year), gender and county of
residence [12]. This registry has maintained data
on all vital statistics – including date of birth,
change(s) of address, date of emigration and exact
date of death – for the Danish population since
1968 [12]. We selected controls using risk-set sam-
pling: each control had to be alive and at risk of a
first VTE hospitalization on the index date of the
case to whom he ⁄she was matched [15]. For three
cases over 100 years of age, 10 controls with an
exact match could not be found. Controls were
assigned an index date identical to that of each
corresponding case.
Hospital and community infections
The DNRP [13] was used to identify patients with in-
or outpatient hospital contact because of specific
infections before their index date. We examined the
VTE risk associated with the following most fre-
quently hospital-diagnosed types of infection: sys-
temic respiratory tract infection (RTI; defined as
pneumonia, acute bronchitis or influenza), urinary
tract infection (UTI), skin infection (including celluli-
tis and erysipelas), intra-abdominal infection
(including gastrointestinal infection) and septicae-
mia [16].
We used the regional prescription database [17]
to identify all antibiotic prescriptions filled by
cases and controls 1 year before their index date.
In Denmark, antibiotics are only available by pre-
scription. Pharmacies in Denmark are equipped
with electronic accounting systems, primarily
used to secure reimbursement from the National
Health Service. For each filled prescription, pa-
tient information regarding the central personal
registry number, the type and amount of drug
prescribed according to the Anatomical Therapeu-
tic Chemical (ATC) classification system and the
date the drug was dispensed are transferred from
the pharmacy to the prescription database [17].
We identified the following antibiotic groups,
which together account for more than 90% of the
total community antibiotic sales in Denmark [11]:
penicillins, cephalosporins, macrolides, quinol-
ones, tetracyclines and sulphonamides. We cate-
gorized these antibiotics according to the commu-
nity-associated infection types for which they are
mainly indicated in Denmark [18]: RTIs, UTIs,
skin or soft-tissue infections and infections trea-
ted with focus-unspecific penicillins. The associ-
ated ICD and ATC codes are provided in
Table S1.
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Patient characteristics
We obtained information from the DNRP [13] on
inpatient (since 1977) and outpatient (since 1995)
diagnoses of the following potential confounding
conditions: cardiovascular disease, chronic obstruc-
tive pulmonary disease (COPD) or asthma, diabetes,
liver disease, obesity, osteoporosis and renal failure.
To account further for potential unmeasured con-
founding arising from frailty and immobility, we
created the variable ‘another recent inpatient admis-
sion’, which includes any inpatient diagnoses other
than the infectious and comorbid diagnoses listed
previously within 3 months before the index date. To
ensure complete identification of subjects with dia-
betes, COPD or cardiovascular disease, we used the
prescription database to obtain data on ever use of
the following drugs since 1998: antidiabetic agents
(oral antidiabetic drugs and insulin) and medicines
for respiratory diseases and cardiovascular diseases
(angiotensin-converting enzyme inhibitors or angio-
tensin-II receptor inhibitors, aspirin, beta-blockers,
calcium channel blockers, clopidogrel, diuretics, ni-
trates, statins and other antihypertensive agents).
We also obtained data on concurrent use of nonste-
roidal anti-inflammatory drugs, oral glucocorticoids,
postmenopausal hormone-replacement therapy and
vitamin K antagonists because these drugs affect
the risk of VTE [3, 4, 19]. Associated ICD codes, ATC
codes and exposure windows for co-medications are
provided in Table S1.
Statistical analysis
Wefirst createdcontingency tables for themainstudy
variables, fromwhichwecalculated thenumbersand
proportions of cases and controls in exposure, medi-
cal and demographic subcategories. We then strati-
fied the contingency tables according to each of the
potential confounding factors listed in Table 1 [20].
Next, we used conditional logistic regression to com-
pute odds ratios (ORs) with 95% confidence intervals
(CIs) for VTE, comparing patients with hospital-diag-
nosed infection and ⁄or antibiotic treatment in the
communitywithin 1 year before their index datewith
the reference groupof subjectswithnohospital-diag-
nosed infection or filled community antibiotic
prescription within the same period. In the primary
analysis, we examined theOR forVTEwithin the first
3 months after infection. Because we used risk-set
sampling of controls, the ORs estimate the incidence
rate ratios (IRRs) [21]. We then fitted models adjust-
ing for the potential confounding factors listed
in Table 1, that is, age (<55, 55–70 and ‡71 years),
gender, the classical VTE risk factors, other comor-
bidities, another recent inpatient admission and
co-medications.We repeated the analyses for: (i) RTI,
UTI, skin infection, intra-abdominal infection and
septicaemia, as defined by hospital diagnoses,
(ii) RTI, UTI, skin or soft-tissue infection and infec-
tions treated with focus-unspecific penicillins, as
defined by filled antibiotic prescriptions, (iii) VTE
registered only as the primary diagnosis, (iv) unpro-
vokedVTE,and (v)DVTandPEindividually.
To examine the impact of time from onset of infection
(date of diagnosis or prescription redemption) and
VTE occurrence, we repeated the analysis for differ-
ent postinfection risk periods, that is, time intervals
between the last hospital diagnosis and ⁄or antibiotic
prescription redemption and VTE: 0–2, 3–4, 5–8, 9–
12, 13–26, 27–39 and 40–52 weeks. We used the
Wald chi-square test to test for a correlation in time
betweenonsetof infectionandVTEoccurrence.
Stratified analyses of the association between any
infection (hospital-diagnosed infection or infection
treated in the community within 3 months before
VTE) andVTEwere conducted using predefined sub-
groupsbasedonage (<55,55–70and‡71 years), gen-
der, presence ⁄absence of cancer, trauma, fracture,
diabetes, cardiovascular disease, COPD or asthma,
obesity or another recent inpatient admission and
the total number of antibiotic prescriptions within
365 daysbefore the index date (1–5, 6–10 or >10pre-
scriptions) [1].
Becausediagnoses of VTE recorded in the emergency
room have a low positive predictive value (approxi-
mately 30%) [22], we performed a sensitivity analysis
excluding such diagnoses. Finally, we quantified the
influence of potential unmeasured confounding on
the observed association by means of a rule-out ap-
proach [23]. We estimated how strongly a single
unmeasured binary confounder would need to be
associatedwith infectionandVTE to fully explain our
findings and illustrated this association graphically
(FigureS1).Weassumedasaworst-casescenario that
the prevalence of such an unmeasured confounder
was30%andthat12%of thepopulationhadan infec-
tionwithin3 months (asobserved for thecontrols).
Results
Patient characteristics
We identified 15 009 patients with VTE and 150 074
population controls. Amongst the VTE cases, 13 259
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(88.3%) had an inpatient hospital diagnosis of VTE,
1080 (7.2%) had a hospital outpatient clinic diagno-
sis and 670 (4.5%) were diagnosed during an emer-
gency room visit. Slightly more than half of the cases
with VTE were women, and the median age was
64 years (Table 1). Within 3 months before the
admission of VTE cases, 1062 cases (7.1%) and
1304 controls (0.9%) had a hospital-diagnosed infec-
tion, and 4356 cases (29.0%) and 16 693 controls
(11.1%) filled an antibiotic prescription in the com-
munity. Compared with controls, many more VTE
patients had cancer, trauma, surgery or another
inpatient admission, or were pregnant, within
3 months before VTE. Other comorbidities, as well
as use of co-medications, were also more common
amongst cases than controls. Amongst all VTE
Table 1 Characteristicsof caseswithvenousthromboembolism(VTE)andpopulationcontrols
AllVTE UnprovokedVTE
Cases (%)
n = 15 009
Controls (%)
n = 150 074
Cases (%)
n = 9113
Controls (%)
n = 79 061
Age
<55 years 4294(28.6) 42 940 (28.6) 2940(32.3) 27 423 (34.7)
55–70 years 4556(30.4) 45 560 (30.4) 2619(28.7) 23 226 (29.4)
‡71 years 6159(41.0) 61 574 (41.0) 3554(39.0) 28 412 (35.9)
Medianage (IQR) 63.5 (52.0–77.0) 63.4 (52.0–77.0) 62.2 (49.0–77.0) 61.1 (48.0–76.0)
Gender, female 7947(52.9) 79 463 (52.9) 4738(52.0) 40 461 (51.2)
ClassicalVTErisk factors
Cancera 3247(21.6) 13 088 (8.7) – –
Pregnancyb 111 (0.7) 371 (0.2) – –
Surgeryb 3341(22.3) 7307(4.9) – –
Traumaor fractureb 1164(7.8) 2803(1.9) – –
Othercomorbidities
Cardiovasculardiseased 9080(60.5) 72 790 (48.5) 5229(57.4) 34 791 (44.0)
COPDorasthmad 3803(25.3) 25 234 (16.8) 2293(25.2) 12 409 (15.7)
Diabetesd 1170(7.8) 9124(6.1) 652 (7.2) 4275(5.4)
Liverdiseasec 238 (1.6) 850 (0.6) 136 (1.5) 383 (0.5)
Obesityc 773 (5.2) 3096(2.1) 434 (4.8) 1511(1.9)
Osteoporosisc 511 (3.4) 3383(2.3) 272 (3.0) 1448(1.8)
Renal failurec 318 (2.1) 1043(0.7) 137 (1.5) 409 (0.5)
Another recent inpatient
admissione
3827(25.5) 6148(4.1) 1110(12.2) 1364(1.7)
Co-medicationsf
HRT 693 (4.6) 6409(4.3) 410 (4.5) 2985(3.8)
NSAIDs 2528(16.8) 10 041 (6.7) 1465(16.1) 4947(6.3)
Oral glucocorticoids 1455(9.7) 3541(2.4) 717 (7.9) 1527(1.9)
VitaminKantagonists 461 (3.1) 3436(2.3) 221 (2.4) 1470(1.9)
COPD,chronicobstructivepulmonarydisease;HRT,postmenopausalhormone-replacement therapy; IQR, interquartile range;
NSAID,nonsteroidal anti-inflammatorydrug.
aPre-existingcanceroracancerdiagnosiswithin3 monthsafter theVTE.
bAny in-oroutpatientdiagnosiswithin3 monthsbefore theVTE.
cAny in-oroutpatienthospitaldiagnosissince1977.
dAny in-oroutpatientdiagnosissince1977oranyfilledprescription for thediseasesince1998.
eAny inpatientdiagnosiswithin3 monthsbefore theVTE,other than for the risk factorsandcomorbidities listed.
fPrescription filled within 60 days (NSAIDs and oral glucocorticoids) or 90 days (HRT and vitamin K antagonists) before the
VTE.
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patients, 9113 (60.7%) appeared to have unpro-
voked VTE. The distribution of characteristics was
similar amongst patients with unprovoked VTE and
the overall group (Table 1).
Risk of VTE
Compared with subjects with no infections during
the year before VTE, the IRR for VTE was 12.5 (95%
CI: 11.3–13.9) for patients with hospital-diagnosed
infection and 4.0 (95% CI: 3.8–4.1) for patients trea-
ted with antibiotics in the community (Table 2).
Adjusting for confounders reduced these IRR values
to 3.3 (95% CI: 2.9–3.8) and 2.6 (95% CI: 2.5–2.8),
respectively. The covariate with the most influence
wasanother recent inpatientadmission.
Amongst hospital-diagnosed infections, the adjusted
IRR for subsequent VTE was 4.9 (95% CI: 4.1–5.9)
for RTI, 1.7 (95% CI: 1.4–2.2) for UTI, 4.1 (95% CI:
Table 2 Incidence rate ratios for venous thromboembolism (VTE) associatedwithhospital-diagnosed infectionsand infections trea-
ted in thecommunity
Incidence rate ratio (95%confidence intervals)
AllVTE UnprovokedVTE
No.of cases ⁄
controls Unadjusteda Adjustedb
No.of cases ⁄
controls Unadjusteda Adjustedb
Noinfectionc 7088 ⁄103 370 1 (reference) 1 (reference) 4684 ⁄56 236 1 (reference) 1 (reference)
Infection,overalld 4836 ⁄17 367 4.2 (4.1–4.4) 2.7 (2.5–2.8) 2595 ⁄7909 4.0 (3.8–4.2) 3.0 (2.8–3.2)
Hospital-diagnosed
infectiond
1062 ⁄1304 12.5 (11.3–13.9) 3.3 (2.9–3.8) 390 ⁄360 13.7 (11.3–16.5) 5.0 (4.0–6.2)
Respiratory tract
infection
561 ⁄499 17.4 (14.8–20.4) 4.9 (4.1–5.9) 248 ⁄166 20.5 (15.7–26.8) 7.7 (5.7–10.4)
Urinarytract infection 243 ⁄414 8.9 (7.3–10.8) 1.7 (1.4–2.2) 91 ⁄109 8.7 (6.1–12.2) 2.0 (1.3–2.9)
Skin infection 145 ⁄171 12.8 (9.7–16.8) 4.1 (3.0–5.7) 57 ⁄43 14.2 (8.9–22.6) 6.2 (3.7–10.5)
Intra-abdominal
infection
147 ⁄212 10.5 (8.1–13.7) 2.4 (1.8–3.3) 29 ⁄39 9.2 (5.1–16.6) 3.1 (1.5–6.3)
Septicaemia 98 ⁄81 18.9 (12.8–28.1) 3.6 (2.3–5.8) 19 ⁄18 13.3 (5.8–30.6) 4.9 (1.9–12.7)
Community
antibiotic
treatmentd
4356 ⁄16 693 4.0 (3.8–4.1) 2.6 (2.5–2.8) 2445 ⁄7731 3.9 (3.6–4.1) 3.0 (2.8–3.1)
Antibiotics for
respiratory
tract infection
939 ⁄2808 5.2 (4.8–5.7) 3.4 (3.0–3.7) 539 ⁄1332 5.2 (4.6–5.8) 3.6 (3.2–4.1)
Antibiotics for
urinary
tract infection
1431 ⁄6630 3.4 (3.2–3.7) 2.0 (1.8–2.1) 722 ⁄2894 3.1 (2.8–3.4) 2.1 (1.9–2.4)
Antibiotics for
skinorsoft
tissue infection
615 ⁄1327 7.2 (6.4–8.1) 3.8 (3.3–4.4) 312 ⁄524 7.5 (6.3–8.9) 5.6 (4.7–6.7)
Focus-unspecific
penicillins
2266 ⁄7636 4.4 (4.2–4.7) 3.1 (2.9–3.3) 1361 ⁄3670 4.6 (4.2–4.9) 3.6 (3.3–3.9)
aAge-,gender-,andcounty-matchedconditional logistic regression.
bAdjusted for the classical VTErisk factors, other comorbidities, another recent hospital admission and co-medicationsuse, as
listed inTable1.Classical risk factorswerenot included,perdefinition, in themodel forunprovokedVTE.
cNohospital-diagnosed infectionorfilledcommunityantibioticprescriptionwithin365 daysbefore theVTE.
dIn- or outpatient hospital-diagnosed infection and ⁄or filled community antibiotic prescription within 3 months before the
VTE.
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3.0–5.7) for skin infection, 2.4 (95% CI: 1.8–3.3) for
intra-abdominal infection and 3.6 (95% CI: 2.3–5.8)
for septicaemia. Amongst infections treated with
antibiotics in the community, the adjusted IRRswere
similar: 3.4 (95% CI: 3.0–3.7) for RTI, 2.0 (95% CI:
1.8–2.1) forUTI, 3.8 (95%CI: 3.3–4.4) for skin or soft-
tissue infection and 3.1 (95% CI: 2.9–3.3) for infec-
tions treatedwith focus-unspecificpenicillins.
The effect estimates were increased similarly for pa-
tients with VTE recorded as the primary diagnosis
(Table S2), for patients with DVT and PE (Table S3)
and forVTEpatients diagnosed in settingsother than
the emergency room (Table S4). IRRswere even high-
er (Table 2) for unprovoked VTE [adjusted IRR values
were 5.0 (95%CI: 4.0–6.2) for patients with hospital-
diagnosed infection,3.0 (95%CI:2.8–3.1) forpatients
treated with antibiotics in the community and 3.0
(95%CI:2.8–3.2)overall].
There was a correlation (P < 0.0001) in time between
onset of infection and VTE occurrence: the highest
VTE risk estimates were observed within the first
2 weeks after onset of all infections, declining gradu-
ally thereafter (Table 3). The incidence rate of VTE
was increased eightfold within the first 2 weeks after
hospital-diagnosed infection,with thehighest risk in-
creases associated with RTIs and skin infections.
VTE rates were increased three- to four-fold between
3 and 8 weeks after infection, and then remained
approximately twofold higher for almost all types of
infection for up to 1 year of follow-up. For antibiotic-
treated infections in the community, the rate of VTE
was increased 5.5-fold within the first 2 weeks. The
highest risk increases were associated with antibiot-
ics typically used for RTIs and skin infections, in
agreement with the findings for hospital-diagnosed
infections. VTE risk estimates gradually declined to
an increase of two- to three-foldwithin 3–8 weeks fol-
lowing most types of infections and remained 1.2- to
1.6-foldhigherafter1 yearofobservation.
The effect estimates forVTEassociatedwith infection
remained elevated in all subgroups Figure 1. How-
ever, the effect estimates were modified by gender,
withaslightly lower IRRamongst female [2.4 (95%CI:
2.3–2.5)] than male subjects [2.8 (95% CI: 2.7–3.1)].
Consistent with the assumption that the effect esti-
mates would be lower amongst those at higher base-
line risk, the estimates were lower amongst patients
with [1.4 (95% CI: 1.2–1.7)] than without [2.7 (95%
CI: 2.6–2.8)] trauma or fracture within 3 months be-
fore VTE and amongst patients with [1.6 (95% CI:
1.4–1.7)] compared with those without [2.9 (95% CI:
2.8–3.1)]anotherrecent inpatientadmission.Shorter
length of antibiotic treatment (1–5 filled prescrip-
tions) was associated with higher effect estimates
than prolonged treatment (>5 filled prescriptions).
Therewerenosubstantial differences in IRRamongst
age subgroups and patients with or without cancer,
diabetes, cardiovasculardisease,COPDorasthmaor
obesity.
Weestimated that anunmeasured confounderwith a
sevenfold higher prevalence amongst patients with
infection thanamongst thosewithout infectionwould
need to increase theVTEriskbya factor of 20ormore
to fully explain our findings, if no increased risk actu-
ally existed (Figure S1). Even stronger confounders
would be required to explain the findings for unpro-
vokedVTE.
Discussion
In this population-based case–control study of
15 009 patients with VTE, we found that acute infec-
tions diagnosed in hospital or treated in the commu-
nity were associated with a markedly increased risk
of VTE. The associationwas strongest within the first
2 weeks after infection onset and gradually declined
thereafter. Similar associations were consistently
found for unprovokedVTE,DVT andPE individually,
and a variety of infection types were associated with
VTE independent of whether they occurred in the
hospital or community setting. We also found that
any inpatient admission within 3 months for condi-
tions other than the classical risk factors for VTE
was strongly associated both with infection and VTE
and modified the effect of infection on VTE occur-
rence.
This is the first study to examine the association be-
tween acute infection and VTE, distinguishing be-
tween infections diagnosed in hospital versus com-
munity care settings, and between various types of
infection. In addition to community-diagnosed RTIs
and UTIs [1], the association also held for skin and
soft-tissue infectionsdiagnosed inthecommunity,as
well as hospital-diagnosed RTIs, UTIs, skin infec-
tions, intra-abdominal infections and septicaemia.
Initial evidence for an association between infection
and VTE was obtained from studies showing a pro-
tective effect on VTE risk of thromboprophylaxis
amongst patients with infectious disease [24–28]. A
case–control study, including636DVTpatients diag-
nosed in general practices between 1990 and 1991
in France, found that the adjusted odds for DVT
were 1.95-fold (95% CI: 1.31–2.92) higher amongst
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patientswith infectious disease comparedwith those
without [9]. In another study including866acutely ill
and immobilized inpatients, the adjustedOR for VTE
within 14 days after infection was 1.74 (95% CI:
1.12–2.75) [8].The typeof infectionwasnotdescribed
in either of these studies [8, 9]. A necropsy review
from the UK showed that amongst patients with fatal
PE,12.2%(26of214)of thosewhohadnotundergone
recent surgery had experienced an acute infectious
episode in the6 weeksbeforedeath [29].Acaseseries
of 7278 DVT and 3755 PE patients using data from
UKgeneralpracticesbetween1987and2004 founda
twofold increased IRR forbothDVTandPEwithin the
first 2 weeks after UTI, a twofold increased IRR for
DVT and 11-fold increased IRR for PEwithin the first
2 weeks after RTI (the later result presumed biased);
the IRR gradually returned to baseline after 1 year
[1]. The association between RTI and VTEwas exam-
ined in another case–control study using data on
11557DVT and 5162 PEpatients whowere included
in a primary care database in the UK between 1991
and 2006 [10]. By excluding patients with an RTI
within 1 month before PE, that study attempted to
avoid possible misdiagnoses of early PE that may
have biased previous studies [1]. Supporting our re-
sults, this laststudy foundan increasedriskofPEbe-
tween 5 and 12 weeks after RTI (adjusted OR, 2.50,
95% CI: 1.33–4.72), an increased risk of DVT within
4 weeks after infection (adjusted OR, 2.64, 95% CI:
1.62–4.29) and increased risks of both PE and DVT
forup to1 yearafter theRTI [10].
Both the early and prolonged associations with VTE
were strongest amongst patients with a hospital-
Adjusted incidence rate ratio† (95% confidence interval)
Overall
Gender
Male
Female
Age
Age <55 years
Age 55–70 years
Age >70 years
Cancer
Yes
No
Trauma or fracture
Yes
No
Diabetis mellitus
Yes
No
Cardiovascular disease
Yes
No
COPD or asthma
Yes
No
Obesity
Yes
No
Recent inpatient admission
Yes
No
Number of filled prescriptions
1–5
6–10
>10
2.7 (2.5–2.8)
2.8 (2.7–3.1)
2.4 (2.3–2.5)
2.7 (2.5–3.0)
2.8 (2.6–3.0)
2.4 (2.3–2.6)
2.6 (2.3–2.8)
2.6 (2.5–2.7)
1.4 (1.2–1.7)
2.7 (2.6–2.8)
2.6 (2.2–3.0)
2.6 (2.5–2.7)
2.6 (2.5–2.7)
2.8 (2.6–3.0)
2.4 (2.2–2.6)
2.7 (2.5–2.8)
2.4 (2.0–3.0)
2.6 (2.5–2.7)
1.6 (1.4–1.7)
2.9 (2.8–3.1)
2.6 (2.4–2.7)
1.9 (1.7–2.2)
1.9 (1.5–2.4)
0.4 0.6 0.8 1 1.4 2 3 4 5
Fig. 1 Stratified analysis of the
associationbetween infection
andvenousthromboembolism
(VTE). In-oroutpatienthospital-
diagnosed infectionand ⁄ orfilled
antibioticprescriptionwithin
3 monthsbefore theVTE.Patients
withouthospital-diagnosed
infectionorfilledcommunity
antibioticprescriptionwithin
365 daysbefore theVTEcom-
prised thereferencegroupwithin
eachcategory.
*Adjusted for theclassical risk
factors, other comorbidities,an-
other recenthospitaladmission
andco-medicationsuse,aslisted
inTable1.
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based diagnosis. The higher increase in the early risk
of VTE may be caused by more severe inflammation
and immobilization associated with hospitalized
compared with community-treated infection epi-
sodes, whereas some of the more sustained risk in-
crease amongst patients with hospital-diagnosed
infectionsmaybedue touncontrolledhigherbaseline
risk of VTE compared with patients treated in the
community.
Venous thromboembolism may also be triggered by
infection-associated systemic inflammation [1, 5].
Weobservedamorepronouncedassociationbetween
subsequent VTE and RTIs and skin infections typi-
callycausedbyGram-positivebacteriasuchaspneu-
mococci, staphylococci and streptococci, compared
with UTIs and intra-abdominal infections. Gram-po-
sitive infectionsmaybeassociatedwithamore severe
and early inflammatory response than typical Gram-
negative infections such as UTIs and intra-abdomi-
nal infections [30]. Thismaybe importantwithregard
to our finding of higher VTE risk estimates for Gram-
positivebacterial infections [30].
The population-based design in the setting of a uni-
versal single-payer healthcare system largely elimi-
nated selection bias stemming from selective inclu-
sion of specific hospitals, health insurance systems
or age groups. Because antibiotic treatment was a
marker for infection, potential nonadherence to
prescribed medication did not influence the results.
Furthermore,wewereable to identify theperiodof in-
creased risk following infection. The data on classical
risk factors that defined provoked VTE have high
validityandspecificity [31].
A potential weakness is that our VTE data were
derived from discharge registry diagnoses, which
may have only 80% validity [22]. However, our
results remained unchanged when we restricted
the analysis to primary VTE diagnoses and ex-
cluded emergency room VTE diagnoses. Another
concern is that individuals with infection in the
community were only included in the analysis if
they consulted their general practitioner. Also, the
date of diagnosis or prescription filling may not
correspond to the actual date of onset of VTE or
infection. However, most patients visit their gen-
eral practitioner within 3 days of onset of symp-
toms [32], so any underestimation of the duration
of the increased risk of VTE was limited to a few
days. In any case, any misclassification of VTE
diagnosis, inaccuracy in onset date or incomplete
ascertainment of infectious diseases would most
likely be nondifferential, leading to underestimates
of effect size.
Early presentation of PEmay bemisdiagnosed as an
RTI, producing amisleadingly strong association be-
tweenRTI and subsequent PE. The samemay be true
for DVT and skin infections. However, such diagnos-
tic misclassification would be unlikely to account for
the increased risks, observed after the first 2 weeks
following infection onset, of DVT after RTI, as well as
of PEafterUTI, skin infection, intra-abdominal infec-
tionorsepticaemia.
Althoughwewere able to control for substantial con-
founding,our resultsmaybevulnerable toconfound-
ing fromunmeasured variables, includinguse of oral
contraceptives, smoking and body mass index [2–4].
Because infection was associated with VTE amongst
both women andmen, oral contraceptive use is unli-
kely tohavehadasubstantial confounding influence.
We adjusted for unmeasured lifestyle factors by con-
trolling for history of COPD and ischaemic heart dis-
ease. Finally, our results could not be explained by
evena strong singleunmeasuredconfounder. In con-
clusion,we found that all typesof acute infectionsare
strongpredictorsofsubsequentVTE.
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